



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



SAR20347

Item No. 29248

CAS Registry No.: 1450881-55-6
Formal Name: 2-(2-chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-oxazolecarboxamide
MF: C₂₁H₁₈ClFN₄O₄
FW: 444.8
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥2 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

SAR20347 is supplied as a solid. A stock solution may be made by dissolving the SAR20347 in the solvent of choice, which should be purged with an inert gas. SAR20347 is soluble in the organic solvent DMSO.

Description

SAR20347 is an inhibitor of the JAK family kinases TYK2 and JAK1-3 (IC₅₀s = 0.6, 23, 26, and 41 nM, respectively, in cell-free assays).¹ It inhibits IL-12-induced TYK2-dependent phosphorylation of STAT4 in NK-92 cells (IC₅₀ = 126 nM) and IL-6-induced JAK1-dependent STAT3 signaling in TF-1 cells (IC₅₀ = 345 nM). SAR20347 (5 μM) inhibits IL-12-induced INF-γ production and reporter gene activity in peripheral blood mononuclear cells (PBMCs). *In vivo*, SAR20347 (60 mg/kg) inhibits the production of serum IFN-γ in mice. SAR20347 also reduces keratinocyte activation and skin levels of IL-12, IL-23, IL-6, IL-22, and IFN-γ in a mouse model of psoriasis induced by imiquimod (Item No. 14956).

Reference

1. Works, M.G., Yin, F., Yin, C.C., *et al.* Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis. *J. Immunol.* **193**(7), 3278-3287 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/10/2019

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM